By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Cerenis Therapeutics, Inc. 

900 Victors Way
Suite 280
Ann Arbor  Michigan  48108  U.S.A.
Phone: 734-769-1110 Fax: 734-769-1132



Company News
Cerenis Therapeutics, Inc. Featured Prominently At The 25th Conference Of The Asian Pacific Association For The Study Of The Liver (APASL) 2/25/2016 2:27:18 PM
Catalent Biologics And Cerenis Therapeutics, Inc. Announce Phase III Trial Of CER-001 In Europe And North America Leveraging GPEx Cell Line Technology 1/28/2016 10:40:56 AM
Cerenis Therapeutics, Inc.: New Data For CER-001 Presented In Key Oral Session At American Heart Association Conference 2015 11/10/2015 12:55:24 PM
Cerenis Therapeutics, Inc. Announces The Results Of The LOCATION Study 7/15/2015 9:42:14 AM
Cerenis Therapeutics, Inc. Announces The Appointment Of A New Chief Medical Officer And New Board Members 2/9/2015 11:00:36 AM
Cerenis Therapeutics, Inc. Receives European Medicines Agency Orphan Drug Designations For CER-001 For The Treatment Of ApoA-I And ABCA-1 Deficiencies 9/3/2014 12:44:17 PM
Cerenis Therapeutics, Inc. Appoints Dr. Richard C. Pasternak As Chairman 9/3/2014 10:59:52 AM
Cerenis Therapeutics, Inc. Reports Two Positive Phase II Studies For HDL Mimetic CER-001 At EAS 6/2/2014 9:09:13 AM
Cerenis Therapeutics, Inc.'s Cholesterol Drug CER-001 Fails In Mid-Stage Trial 1/2/2014 6:57:02 AM
Cerenis Therapeutics, Inc. Selected as a 2012 Red Herring Top 100 Europe 4/27/2012 11:47:41 AM